Zacks Research Downgrades Zealand Pharma A/S (OTCMKTS:ZLDPF) to Strong Sell

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Thursday,Zacks.com reports.

Several other analysts also recently weighed in on the stock. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

ZLDPF stock opened at $52.68 on Thursday. The company has a market capitalization of $3.77 billion, a PE ratio of 8.74 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12. The company’s 50 day moving average price is $45.69 and its two-hundred day moving average price is $49.49.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, August 13th. The company reported $8.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $8.47. Zealand Pharma A/S had a net margin of 58.86% and a return on equity of 18.53%. The company had revenue of $698.62 million during the quarter, compared to analysts’ expectations of $692.12 million. As a group, analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.